Geron Corporation [NASDAQ: GERN] plunged by -$0.06 during the normal trading session on Friday and reaching a high of $1.76 during the day while it closed the day at $1.69. The company report on December 11, 2020 that Geron Announces Opening of IMpactMF Phase 3 Clinical Trial in Refractory Myelofibrosis.
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, announced the opening for patient screening and enrollment of the IMpactMF Phase 3 clinical trial of imetelstat, a first-in-class telomerase inhibitor, in refractory myelofibrosis (MF).
“As Geron’s second registration-enabling Phase 3 trial in hematologic myeloid malignancies, the IMpactMF trial represents a milestone for our Company,” said Aleksandra Rizo, M.D., Ph.D., Geron’s Chief Medical Officer. “The IMpactMF trial will evaluate imetelstat in a poor-prognosis refractory MF patient population to confirm the clinical benefits of extended overall survival and symptom improvement observed in our IMbark Phase 2 trial, as well as the reductions in abnormal clones and mutation burden demonstrating disease-modifying activity of imetelstat.”.
Geron Corporation stock has also loss -2.31% of its value over the past 7 days. However, GERN stock has declined by -9.87% in the 3 months of the year. Over the past six months meanwhile, it has lost -13.33% and gained 24.26% year-on date.
The market cap for GERN stock reached $543.30 million, with 318.80 million shares outstanding and 296.50 million shares in the current float. Compared to the average trading volume of 2.78M shares, GERN reached a trading volume of 6244541 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Geron Corporation [GERN]:
Stifel have made an estimate for Geron Corporation shares, keeping their opinion on the stock as Buy, with their previous recommendation back on August 03, 2020. While these analysts kept the previous recommendation, B. Riley FBR raised their target price to Buy. The new note on the price target was released on November 19, 2019, representing the official price target for Geron Corporation stock. Previously, the target price had yet another raise to $4, while H.C. Wainwright analysts kept a Buy rating on GERN stock.
The Average True Range (ATR) for Geron Corporation is set at 0.08, with the Price to Sales ratio for GERN stock in the period of the last 12 months amounting to 1358.25. The Price to Book ratio for the last quarter was 2.32, with the Price to Cash per share for the same quarter was set at 0.71.
GERN stock trade performance evaluation
Geron Corporation [GERN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -2.31. With this latest performance, GERN shares dropped by -11.05% in over the last four-week period, additionally sinking by -13.33% over the last 6 months – not to mention a rise of 19.01% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for GERN stock in for the last two-week period is set at 39.78, with the RSI for the last a single of trading hit 37.84, and the three-weeks RSI is set at 42.03 for Geron Corporation [GERN]. The present Moving Average for the last 50 days of trading for this stock 1.8424, while it was recorded at 1.7100 for the last single week of trading, and 1.6695 for the last 200 days.
Geron Corporation [GERN]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Geron Corporation [GERN] shares currently have an operating margin of -15761.96. Geron Corporation’s Net Margin is presently recorded at -14901.74.
Return on Total Capital for GERN is now -45.97, given the latest momentum, and Return on Invested Capital for the company is -43.51. Return on Equity for this stock declined to -43.82, with Return on Assets sitting at -39.08. When it comes to the capital structure of this company, Geron Corporation [GERN] has a Total Debt to Total Equity ratio set at 1.89. Additionally, GERN Total Debt to Total Capital is recorded at 1.85, with Total Debt to Total Assets ending up at 1.54. Long-Term Debt to Equity for the company is recorded at 1.63, with the Long-Term Debt to Total Capital now at 1.60.
Reflecting on the efficiency of the workforce at the company, Geron Corporation [GERN] managed to generate an average of -$1,490,174 per employee. Receivables Turnover for the company is 0.47 with a Total Asset Turnover recorded at a value of 0.00.Geron Corporation’s liquidity data is similarly interesting compelling, with a Quick Ratio of 9.60 and a Current Ratio set at 9.60.
Earnings per share (EPS) analysis for Geron Corporation [GERN] stock
With the latest financial reports released by the company, Geron Corporation posted -0.15/share EPS, while the average EPS was predicted by analysts to be reported at -0.2/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 25.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for GERN. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Geron Corporation go to 5.00%.
Geron Corporation [GERN]: Insider Ownership positions
There are presently around $291 million, or 55.80% of GERN stock, in the hands of institutional investors. The top three institutional holders of GERN stocks are: RA CAPITAL MANAGEMENT, L.P. with ownership of 30,126,299, which is approximately 0% of the company’s market cap and around 0.16% of the total institutional ownership; BLACKROCK INC., holding 24,589,040 shares of the stock with an approximate value of $41.55 million in GERN stocks shares; and ECOR1 CAPITAL, LLC, currently with $32.5 million in GERN stock with ownership of nearly 0% of the company’s market capitalization.
Positions in Geron Corporation stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 83 institutional holders increased their position in Geron Corporation [NASDAQ:GERN] by around 34,128,917 shares. Additionally, 37 investors decreased positions by around 18,272,469 shares, while 47 investors held positions by with 120,025,759 shares. The mentioned changes placed institutional holdings at 172,427,145 shares, according to the latest SEC report filing. GERN stock had 26 new institutional investments in for a total of 14,997,695 shares, while 14 institutional investors sold positions of 340,840 shares during the same period.